Abstract
Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapies or in combination, in preclinical and clinical settings. A number of intriguing options have emerged, and it is hoped that further progress will lead to significant changes in the natural history of MPNs.
Keywords:
Combination; Myelofibrosis; Myeloproliferative neoplasm; Novel; Targeted; Therapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Epigenesis, Genetic / drug effects
-
Humans
-
Interferons / pharmacology
-
Interferons / therapeutic use
-
Janus Kinases / antagonists & inhibitors
-
Molecular Targeted Therapy
-
Myeloproliferative Disorders / diagnosis
-
Myeloproliferative Disorders / genetics*
-
Myeloproliferative Disorders / metabolism
-
Myeloproliferative Disorders / therapy*
-
Philadelphia Chromosome*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Signal Transduction / drug effects
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Interferons
-
Janus Kinases